ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Down 9.7% in October

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 2,050,000 shares, a drop of 9.7% from the September 30th total of 2,270,000 shares. Based on an average daily trading volume, of 352,600 shares, the short-interest ratio is presently 5.8 days.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. StockNews.com downgraded shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, September 7th. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a report on Tuesday, October 22nd. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an "overweight" rating and a $68.00 price objective for the company. Raymond James increased their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a research report on Wednesday, September 18th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $77.33.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. F M Investments LLC acquired a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at $3,686,000. James Investment Research Inc. acquired a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at $243,000. New York State Teachers Retirement System raised its holdings in shares of ANI Pharmaceuticals by 1.7% in the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company's stock valued at $1,439,000 after purchasing an additional 394 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of ANI Pharmaceuticals by 64.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company's stock valued at $241,000 after purchasing an additional 1,582 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its holdings in shares of ANI Pharmaceuticals by 5.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company's stock valued at $564,000 after purchasing an additional 464 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Down 0.8 %

ANIP stock traded down $0.50 during midday trading on Wednesday, hitting $58.51. The company's stock had a trading volume of 139,998 shares, compared to its average volume of 211,460. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals has a 52-week low of $48.20 and a 52-week high of $70.81. The firm has a market capitalization of $1.23 billion, a P/E ratio of 36.57 and a beta of 0.71. The firm has a 50-day simple moving average of $59.33 and a 200-day simple moving average of $61.90.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company had revenue of $138.00 million during the quarter, compared to analysts' expectations of $129.09 million. During the same quarter last year, the company posted $1.06 EPS. The firm's revenue was up 18.5% compared to the same quarter last year. As a group, equities analysts forecast that ANI Pharmaceuticals will post 3.58 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.